'Nerve Support' Did Not Save NeuropAWAY

which exact lines did fda quote back to vasocorp?

FDA quoted three lines lifted directly from VasoCorp's own site in the July 9, 2026 letter to VasoCorp, Inc. (CMS #732724): a product tagline, a body-copy claim, and a distribution detail buried in the About Us page. None of the three names peripheral neuropathy outright, and none needed to.

We compared the tagline against ordinary neuropathy-niche copy, and it barely differs from the category default — 'burning, tingling, and numbness' is how most of this vertical describes the condition without ever naming it. FDA read it as a disease symptom cluster anyway. That's the exact mechanism 21 CFR 101.93(g)(2)(ii) describes: an effect on 'characteristic signs or symptoms of a specific disease or class of diseases, using scientific or lay terminology,' per the regulation's current text.

why did 'supports damaged and needy nerves' fail as structure/function?

It failed because 'damaged' nerves aren't a structure/function question under FDA's own rule — they're a disease question. 21 CFR 101.93(g)(1) defines disease as 'damage to an organ, part, structure, or system of the body such that it does not function properly,' and a nerve described as damaged fits that definition before any other word in the sentence gets read.

'Needy' pushes the sentence further into disease territory rather than out of it. It reads as informal, almost conversational, but FDA treats lay terminology as equivalent to clinical vocabulary under the same signs-and-symptoms test — the softness of the word does nothing to change which test applies.

Nerve damage isn't a normal process the body regulates — it's harm already done.

We've tracked this exact substitution fail before in a different gland: the same 'support' hedge collapses in thyroid copy for an almost identical reason, because the softened verb never overrides what the surrounding noun already describes.

how did the product name become part of the evidence under 101.93(g)(2)(iv)?

The name NeuropAWAY became evidence on its own because 21 CFR 101.93(g)(2)(iv)(A) lists the name of the product as one of the ways a disease claim gets made, independent of any sentence around it. FDA doesn't need supporting body copy to read a name built from a symptom category as evidence of intended use.

FDA has used this exact provision before, and NeuropAWAY isn't an outlier case. In a November 2022 warning letter to BergaMet North America LLC, FDA cited the product name 'Cholesterol Command' as evidence on its own, alongside the express claim that 'BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL,' from FDA's warning letter to BergaMet. NeuropAWAY runs the identical structure in a different vertical: a name built from the symptom category, paired with body copy that never says 'neuropathy,' reviewed by FDA as one package rather than as separable risk. Renaming the product to something generic wouldn't have saved the rest of the copy, but it would have removed one line from the evidence FDA didn't strictly need to reach its conclusion.

A generic name wouldn't have saved NeuropAWAY's copy on its own, since the tagline and body claim were doing plenty of damage independently. It would only have removed one line from the file.

why did fda cite the pharmacy diabetes aisle in an about-us page?

FDA cited the pharmacy placement because context, not just copy, decides whether a statement implies a disease. Under 21 CFR 101.93(g)(2), FDA states it will consider the context in which a claim is presented, and a symptom-cluster tagline sitting next to a distribution claim that puts the product 'in the diabetes section of major pharmacies' is exactly the kind of context the rule was written to catch.

Retail placement isn't advertising copy in the ordinary sense — nobody wrote 'this treats diabetic neuropathy' anywhere on the page. But we read the same pattern across other letters in this research: organic content, testimonials and even where a product physically sits on a shelf all count as evidence of intended use once FDA starts building a file.

The About Us page never mentioned a symptom. It mentioned a shelf, and that was enough.

what does the 502(f)(1) practitioner-supervision finding mean for a lay-marketed offer?

It means no rewrite of the label saves the product, because FDA found peripheral neuropathy is a disease that isn't 'amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner' — VasoCorp's own quoted finding from the July letter. Under section 502(f)(1), that finding alone makes the product misbranded for lacking adequate directions for lay use, on top of being misbranded for making an unauthorized drug claim.

FDA's standard reasoning for this category, quoted in closing language across multiple letters including its letter to JLM Nutritionals, treats a disease as one where a product is 'intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner' — and for that subcategory, no version of the instructions panel cures it, because a layperson can't safely self-manage the underlying condition regardless of what the label says.

This finding closes the file regardless of any rewrite.

why is a percentage improvement figure the most dangerous sentence on the page?

A percentage improvement figure is the most dangerous sentence on the page because it converts a vague support claim into a measurable efficacy claim, and both FDA and FTC read a specific number as evidence of a treatment effect — even when it comes from a customer review instead of the brand's own copy.

FDA has quoted numbers exactly this way before. In a different vertical, it cited a customer testimonial reporting an HbA1c drop from 10.5% to 9.5%, posted on the brand's own social accounts, as evidence of intended use in FDA's warning letter to Lysulin, Inc. A nerve-pain percentage lifted from a five-star review works the same way — the advertiser didn't write it, but FDA attributes it anyway once the brand reposts or replies to it, which is why the same trap catches your customer service team's Facebook comments.

The same principle broke a hedged cholesterol claim too: qualifying language didn't rescue an implied disease claim in 'lowers cholesterol, however qualified' is a drug claim, and a specific number functions the same way here — it's evidence, not proof of caution.

is there any version of this copy that survives?

Yes, but nerve support claim compliance survives only within a narrower lane than most advertisers assume, and it can't include any of the four elements that sank NeuropAWAY. Copy limited to occasional, non-specific discomfort — with no symptom cluster resembling a diagnosis, no product name built from the condition, no diabetes-adjacent distribution context and no percentage figure from a testimonial — stays inside 21 CFR 101.93(f)'s structure/function lane. If your landing page runs anything closer to VasoCorp's tagline, treat this letter as the floor, not the ceiling, of what FDA will read into it.

That's a genuinely narrow lane, and it's narrower than most nerve-health copy running today. The FDA-permitted version reads almost clinically dull next to typical creative, which is precisely why so few advertisers choose to operate inside it.

We could not verify whether VasoCorp pulled NeuropAWAY from pharmacy diabetes shelves after the letter; a dated shelf photo or a follow-up FDA close-out notice would settle it.

FDA has let narrow, carefully bounded language hold up before — the same close-reading exercise is what kept an appetite suppressant claim lawful in a different niche, because the wording never touched the disease-level population it was regulating around.

The safe copy is smaller than the market wants it to be.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, 'Balance' and 'Support' Do Not Save Thyroid Copy, Few Thyroid Letters Does Not Mean a High Ceiling, T3 Conversion and Halogen Angles Under 101.93(g), 'Lowers Cholesterol, However Qualified' Is a Drug Claim, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.